Anavex Life Sciences and Partex N.V. Group announced a strategic partnership with the overall ambition to reshape the future of the biopharma business model. By combining Anavex’s innovative small molecule precision medicine drug development platform and Partex’s Artificial Intelligence enabled drug development and healthcare sales marketing, this collaboration is intended to drive efficiency, effectiveness, and innovation across the value chain with patient-centric focus at every step. Under the partnership, Anavex and Partex intend to co-develop a disease-focused Patient App ecosystem. The first feature will be to inform patients and caregivers on preventive and curative options available in clinics and on the market. “As a biopharmaceutical Company with a proprietary late stage pipeline for CNS indications, Anavex brings expertise in precision medicine drug development to the partnership and we are excited to collaborate with Partex and fully leverage AI to expand beyond our R&D into healthcare sales marketing to bring better treatment options to patients in a patient centric way,” said, Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AVXL:
- Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome
- Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem
- Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
- ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
- Anavex receive compassionate use authorization for child patients with Rhett